Bell’s Palsy is an idiopathic unilateral facial nerve paralysis.

Since the 2009 Cochrane review¹ showing that antivirals added no benefit to corticosteroids in Bell’s Palsy, I stopped prescribing them. The NNT.com site has concluded the same. Looking at the literature a little more, the recommendations are a little murkier. Some groups are still advocating for antivirals for severe cases, because there may be a very small but questionably positive benefit.

• “Because of the possibility of a modest increase in recovery, patients might be offered antivirals (in addition to steroids) (Level C). Patients offered antivirals should be counseled that a benefit from antivirals has not been established, and, if there is a benefit, it is likely that it is modest at best”²
• UpToDate: “For the subgroup of patients with severe facial palsy at presentation, defined as House-Brackmann grade IV or higher, we suggest early combined therapy with prednisone (60 to 80 mg per day) plus valacyclovir (1000 mg three times daily) for one week rather than glucocorticoids alone (Grade 2B).”
• “The authors conclude that although a strong recommendation for adding antiviral agents to corticosteroids to further improve the recovery of patients with severe Bell palsy is precluded by the lack of robust evidence, it should be discussed with the patient.”³
• “Antiviral agents, when administered with corticosteroids, may be associated with additional benefit.”⁴

PV Card: Treatment of Bell’s Palsy

Adapted from [1, 2, 4]
Go to ALiEM (PV) Cards for more resources.

Thanks to Dr. Kristin Berona (UCSF-SFGH EM resident) for the idea and notes!

References

1. Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F. Antiviral treatment for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2009;(4):CD001869. [PubMed]
2. Gronseth G, Paduga R, American A. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79(22):2209-2213. [PubMed]
3. van der, Rovers M, de R, van der. A small effect of adding antiviral agents in treating patients with severe Bell palsy. Otolaryngol Head Neck Surg. 2012;146(3):353-357. [PubMed]
4. de A, Al K, Guyatt G, et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA. 2009;302(9):985-993. [PubMed]

What is your diagnostic approach to the acutely vertiginous patient?

The bottom-line question is: Is the cause peripheral or central in etiology?

In this great 2011 systematic review article in CMAJ on Acute Vestibular Syndrome (AVS), the authors review how (un)predictive elements of the history and physical exam are. By definition of AVS, symptoms must be continuous for at least 24 hours and have no focal neurologic deficits.

Frighteningly, the authors report many of the signs and symptoms (type of dizziness, hearing loss, patterns of nystagmus, Hallpike-Dix) are not as predictive as we classically are taught!

The take home point is to learn and incorporate the 3-part HINTS exam into your diagnostic approach (see bottom box on card). It is reported to be as good as a diffusion-weighted MRI for diagnosing a posterior stroke. The steps are:

1. Do the horizontal head impulse test. (Normal = central cause)
2. Check for directionally-alternating nystagmus movement on left and right gaze.
3. Do the alternate cover test.

PV Card: Acute Vestibular Syndrome vs Stroke | The HINTS Exam

Adapted from [1]
Go to ALiEM Cards for more resources.

There is a helpful 10-minute video showing normal and abnormal HINT findings:

• Head impulse testing
• Nystagmus testing
• Testing of skew

VIDEO LINK: http://emcrit.org/misc/posterior-stroke-video/

Thanks to Dr. Brian Resler (UCSF-SFGH EM resident) for giving me the heads up about this at Followup Conference!

Reference

1. Tarnutzer A, Berkowitz A, Robinson K, Hsieh Y, Newman-Toker D. Does my dizzy patient have a stroke? A systematic review of bedside diagnosis in acute vestibular syndrome. CMAJ. 2011;183(9):E571-92. [PubMed]